MedPath

Effect of Methylprednisolone on Glucose Homeostasis in Patients Undergoing Total Hip- and Knee-arthroplasty

Phase 3
Completed
Conditions
Osteoarthrosis
Interventions
Registration Number
NCT02332603
Lead Sponsor
Rigshospitalet, Denmark
Brief Summary

This study evaluates the pathophysiological effects of a single dose of Methylprednisolone administered prior to total hip- and knee-arthroplasty surgery. The investigators examine the effect on blood glucose homeostasis.

Half of participants will receive intravenous Solu-Medrol 125 mg, while the other half will receive placebo.

The investigators hypothesize that the glucose homeostasis remains equally stable in the group receiving Methylprednisolone as in the group receiving placebo.

Detailed Description

The anti-inflammatory effects of glucocorticoids are well known. The beneficial effects on postoperative pain, postoperative nausea and vomiting are well-documented.

Glucocorticoid might change the glucose metabolism as it induces insulin-resistance. Glucocorticoids are known to reduce the insulin-mediated glucose uptake by reducing the muscle glycogen synthase activity.

The effect of a single high dose of glucocorticoid is poorly described in the literature, and therefore calls for further investigation.

This study is embedded in a primary study registrated as: NCT02319343

For further details please view the EudraCT registration:

EudraCT nr.: 2014-003395-23

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
134
Inclusion Criteria
  • Osteoarthrosis
  • Undergoing total unilateral hip- or knee arthroplasty surgery
  • Speak and understand Danish
  • Have given informed consent
Exclusion Criteria
  • Revision or bilateral hip- or knee-arthroplasty surgery
  • General anaesthesia
  • Allergy or intolerance towards Methylprednisolone
  • Local or systemic infection
  • Permanent systemic treatment with steroids within 30 days preoperatively
  • Insulin-dependent diabetes
  • Active treatment of ulcer within 3 months preoperatively
  • Cancer disease
  • Autoimmune disease incl. rheumatoid arthritis
  • Pregnant or breast feeding women
  • Menopause <1 year

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
MethylprednisoloneMethylprednisolonePreoperative single high dose of Solu-Medrol 125 mg iv.
Isotonic Sodium ChlorideIsotonic Sodium ChloridePreoperative single dose of isotonic Sodium Chloride
Primary Outcome Measures
NameTimeMethod
Changes in plasma blood glucose from baseline (before surgery) to 48 hours after surgerybaseline to 48 hours
Secondary Outcome Measures
NameTimeMethod
Changes in plasma C-peptide from baseline (before surgery) to 48 hours after surgerybaseline to 48 hours

Trial Locations

Locations (1)

Bispebjerg Hospital

🇩🇰

Copenhagen NV, Denmark

© Copyright 2025. All Rights Reserved by MedPath